Rapamycin treatment for a child with germline PTEN mutation

Nature Clinical Practice Oncology

Volumn 5, Issue 6, 2008, Pages 357-361

  Marsh, Deborah J ^a   Trahair, Toby N ^b   Martin, Janet L ^a   Chee, Wey Yeeng ^a   Walker, Jan ^b   Kirk, Edwin P ^b   Baxter, Robert C ^a   Marshall, Glenn M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; GROWTH HORMONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C;

ABDOMEN; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ARTICLE; BREAST HAMARTOMA; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL TUMOR; CONTROLLED STUDY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HUMAN CELL; HYPOPROTEINEMIA; IN VITRO STUDY; INFANT; IRON DEFICIENCY ANEMIA; MALE; MALNUTRITION; MEDIASTINUM; MULTIPLE CANCER; NOSE FEEDING; PELVIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; SIROLIMUS;

EID: 44649203072     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1112     Document Type: Article

References (22)

1. Biesecker LG et al. (1999) Proteus syndrome: Diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet 84: 389-395
2. Zhou X et al. (2001) Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358: 210-211
3. Smith JM et al. (2002) Germline mutation of the tumour suppressor PTEN in Proteus Syndrome. J Med Genet 39: 937-940
4. Tee AR and Blenis J (2005) mTOR, translational control and human disease. Semin Cell Dev Biol 16: 29-37
5. Luan FL et al. (2002) Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73: 1565-1572
6. Zbuk KM and Eng C (2007) Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7: 35-45
7. Marsh DJ et al. (1998) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7 507-515
8. Alessi DR et al. (2006) LKB1-dependent signaling pathways. Annu Rev Biochem 75: 137-163
9. Franz DN et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59: 490-498
10. Faivre S et al. (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688
11. Costa LJ et al. (2007) Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 69 596-602
12. Masiello D et al. (2007) Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther 6: 195-201
13. Doherty L et al. (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 156-158
14. Wilkie AO (2007) Cancer drugs to treat birth defects. Nat Genet 39: 1057-1059
15. Drolet BA et al. (1999) Hemangiomas in children. N Engl J Med 341: 173-181
16. Firth SM and Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854
17. Baron-Hay S et al. (2004) Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10: 1796-1806
18. Ho PJ and Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperpasia. Clin Endocrinol (Oxf) 46: 145-154
19. Levitt RJ et al. (2005) PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336: 1056-1061
20. Martin JL and Baxter RC (2007) Expression of insulin-like growth factor binding protein-2(IGFBP-2) by MCF-7 breast cancer cells is regulated through the P13-kinase/AKT/mTOR pathway. Endocrinology 148: 2532-2541
21. Mehrian-Shai R et al. (2607) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and P13K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104: 5563-5568
22. Georgescu MM et al. (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96: 10182-10187